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A. Introduction 
A.1. Oral squamous cell carcinoma (OSCC) 
A.1.1. Definition and epidemiology 
Oral cancer is a malignant disease that affects the structure of the mouth and its 
tissues. It can arise from the mouth tissue and may be a result of metastatic 
invasion from a distant body location or a junction with a tumor of an adjacent 
tissue [5]. Squamous cell carcinoma (SSC) is found in 90% of various oral cancer 
types worldwide [6]. SCC, which is also considered as one important type of head 
and neck malignancies, is the most common malignant transformation that can 
also arise from the “paranasal sinuses, nasal cavity, pharynx and larynx”. 
Microscopically, OSCC results after a series of tissue morphological 
premalignant changes starting from tissue hyperplasia then mild to severe 
epithelial dysplasia (also known as carcinoma in situ) then malignant carcinoma 
(Fig. 1) [4]. The most common habitual etiological risk factors that lead to OSCC 
are tobacco and alcohol consumption, which when combined have synergic 
action [7]. Another major causative risk factor that has recently been intensively 
studied, is the persistent infection with human papillomavirus which is particularly 
important in oropharyngeal squamous cell carcinoma including tonsillar and base 
of the tongue cancer [8-10]. As for most cancers, squamous cell carcinoma is the 
result of genetic alterations that lead to malignant behavior, in which cellular DNA 
undergoes increased exposure to extrinsic damaging factors and a decrease in 
the function of intrinsic DNA protecting factors. Although many patients are 
unaware of its presence, oral cancer is found to be the eighth most frequent 
cause of death among other human body cancer diseases. [11]. 
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Figure 1: Histopathological stages of malignant transformation in epithelial squamous cell 
carcinoma (HNSCC tissue samples). Stages of malignant transformation in which normal 
epithelial tissue (slide a) undergoes hyperplastic cellular activity to from epithelial 
hyperplasia (slide b). Persistent etiological factors then lead to mild dysplasia (slide c) then 
to the last precancerous lesion; carcinoma insitu (slide d) and finally reaching the phase of 
invasive squamous cell carcinoma (slide e). Clinically, Hyperplastic changes need at least 
regular professional control while dysplastic to invasive neoplastic changes demand surgical 
intervention or other cancer therapy. Modified from [4]. 
a b 
c d 
e 
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In general, mouth cancers including the lip, salivary gland, mouth, gum and 
tongue cancers have a 2.6% worldwide incidence rate with about 212.000 new 
cases every year. The occurrence in males (141.200 cases yearly) is more than 
females (70.300 new cases yearly) with a gender-ratio (M:F) of 2 to 1. The highest 
incidence rate in reference to the geographic classification is in Melanesia , “a 
sub-region of Oceania, northeast of Australia” and South Central Asia. In 
Western, North and South Europe, nearly 32.200 cases are diagnosed every 
year, where the prevalence of key risk factors like tobacco and alcohol 
consumption in these areas is at increasing levels [12]. Statistical studies 
concluded that the sixth leading cancer among the most common malignancies 
worldwide is the head and neck cancer. In the meantime, 25% to 40% of the oral 
squamous cell carcinomas are affecting the tongue tissue [13]. In the European 
Union including Germany, oral and pharyngeal tumor is the seventh tumer 
affecting men and account for 3.5% of tumers and sixteenth occurring tumer 
among women and accounts for 1.5% of occurring tumors. In Germany alone, 
ten thousand new cases of oral and pharyngeal tumers are diagnosed yearly [14, 
15]. In 2004, 40.100 death cases in Europe resulting from oral and pharyngeal 
cancer were registered [14]. The overall five-year relative survival rate of oral 
cancer patients in Germany is 54.6%. OSCC survival rate is in general statistically 
associated with the age of the patient, tumor grade and stage for both sexes. In 
Germany for example, the five-year survival rate is around 54.6%. Although the 
incidence of OSCC is increasing in women, it is still less than in male patients, in 
which the incidence in women is 8% lower than in men among all age groups 
under 75 years [16]. 
A.1.2. Detection of OSCC 
In general, oral cavity cancer can be detected early using various diagnostic 
methods. Among these are conventional methods such as taking a tissue biopsy 
and modern non-invasive methods such as “oral brush biopsy, saliva-based oral 
diagnosis and optical biopsies”. Optical biopsy and saliva-based oral diagnosis 
techniques are found to be promising and effective measures in diagnosing oral 
squamous cell carcinoma [17]. Other cancer diagnostic modalities have, to some 
extent, proven their efficiency in detecting malignant changes. Although, it is 
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always required to take a tissue biopsy and use newly developed referral criteria 
for definitive confirmation of any malignant change [18]. 
 
Early detection of the signs and symptoms of SCC of the head and neck can 
largely prompt the diagnosis of the disease. Unfortunately, there is no known 
better proven screening method yet other than the usual clinical diagnostic means 
like regular clinical examination and inspection in areas of high disease 
prevalence [19]. Furthermore, delays in disease detection can play a role in 
prognosis determination of oral cancer. In addition, the patients’ age, the rate and 
nature of disposition to etiological factors are important to the tumor’s behavior 
influential factors [20]. The high prevalence of OSCC in developing countries in 
comparison to developed countries could be related to the latency in disease 
detection, which in turn limits the proper treatment choices [21].  
 
A.1.3. Management of OSCC 
Choosing the appropriate treatment and decision making for the management of 
OSCC, as well as for other head and neck squamous cell carcinomas, is usually 
complicated and requires the systematic collaboration of the dentist with head 
and neck surgeons, medical oncologists, radiotherapy specialists as well as 
plastic surgeons. For treatment guidance, important factors like the primary 
malignancy site and stage as well as the possibility of a surgical tumor resection 
should be considered. Other patient-related factors like swallowing, airways and 
the patients’ desire for preserving the affected organ and the presence of other 
morbid diseases must be considered [22].  
 
In combination to surgical treatment and adjuvant radiotherapy, which are the 
best known effective treatment methods, drugs with cytostatic effects such as 
cisplatin, 5-fluorocil (5-FU) and paclitaxel as well as for palliative treatment proved 
to be very efficient in treating oral cancer [23] , [24] & [25]. The most important 
factor that guides the treatment planning is the accurate staging, which is usually 
carried out by an oral and maxillofacial surgeon and is usually based on the 
radiographic examination with computer tomography (CT) or magnetic resonance 
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imaging (MRT) [16] or mostly both. Distant metastasis of the OSCC can take 
place in the lungs, which is the most common place of metastasis that makes the 
chest imaging a very important routine initial assessment tool. Other areas and 
organs like mediastinal lymph nodes, liver and skeletal bone also could be 
affected [22]. To detect the presence of a distant malignant invasion, the 
combination of radiological techniques like CT imaging and the positron emission 
tomography (PET) scan after premedication with radioactive tracer agents like 
[18F] Fluorodeoxyglucose (18F-FDG) is usually a routine procedure, which is 
known as PET/CT [26]. This diagnostic procedure has proven to be efficient in 
detecting body distant malignant invasions as well as lymph node metastasis or 
both together [27]. 
A.2. Cancer stem cell compartments (CSCs), CD44 a CSCs 
extracellular marker in oral and head and neck 
squamous cell carcinoma (HNSCC) and their role in 
tumor 
A.2.1. Cancer stem cells (CSCs) in OSCC 
Stem cells in general are type of cells that have the capability of self-renewal and 
the differentiation to generate mature cells of a particular tissue [28]. Also known 
as physiological stem cells, stem cells have two types: embryonic and adult stem 
cells. Embryonic stem cells arise from the inner mass of the mammalian 
blastocyst and can differentiate into cells of the known three germ layers that can 
develop to all tissue types. On the other hand, adult stem cells have more limited 
differentiation ability which is more restricted to cell types of the tissue where they 
are located and can assist in tissue homeostasis, regeneration of new cells as 
well as their major role in the pathogenesis of various diseases including cancer, 
which then can be called cancer stem cells (CSCs). CSCs can be found within 
cancer cells and have the ability of self-renewal to serve as precursors for tumor 
cells sustaining tumor growth [29]. CSCs were first detected in myeloid leukemia. 
Studies on mice and humans have increased the evidences of their importance 
in the development of many solid tumors including oral cancer. Due to biological 
variations and so often experimental technical reasons, the presence of CSCs in 
solid tumors is variable and may have no similar properties from primary CSCs. 
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More importantly, CSCs have shown more resistance to chemo- as well as 
radiotherapy [30]. CSCs are also known to share similar normal stem cell 
capabilities like the state of inactivity, resistance to drugs and toxins due to the 
involvement of ATP-binding cassette transporters (ABC transporters) expression 
ability, active DNA repair capacity and resistance to programmed cell death 
(apoptosis). These factors can lead to increased chances of CSCs survival 
against chemotherapy and the evolution of more tumor cell populations [31].  
 
In recent studies, it is becoming more evident that most, if not all, malignancies 
are developing from the so called cancer stem cell compartment [1, 2, 32]. Also, 
from clinical observation of tumor recurrence and relapse after treatment with 
chemotherapy, theories arose initially to doubt the existence of residual stem cells 
after therapy correlating to their responsibility for tumor regeneration. Secondly, 
they encouraged the development of new treatment modalities that can target the 
critical CSCs cancer regenerating and self-renewal properties resulting in more 
treatment efficiency in head and neck cancer as well as in other cancers [1, 2]. 
Although not all tumor cells have the ability to metastasize, epithelial CSCs can 
metastasize firstly through a process which utilize the so-called epithelial-
mesenchymal transition (emT), an instrumental event in the metastatic process 
and secondly with the help of the disturbed cellular homeostasis [1, 2]. 
A.2.2. CD44 and cancer stem cells CSCs in OSCC 
In order to understand the involvement of CSCs and to study the mechanism of 
carcinogenesis in head and neck squamous cell carcinoma, CD44 extracellular 
receptor must be studied. CD44 glycoprotein is an extracellular matrix receptor, 
which main site of action is the cell surface and is one of the most recognized 
and studied CSCs related marker [29, 33, 34]. In addition to its role in lymphocytic 
function, cellular adhesion, migration and homing, CD44 protein overexpression 
in CSCs can play major roles in neoplastic diseases like in head and neck 
cancers, breast cancer, prostate cancer and ovarian cancer [3, 35, 36]. On the 
contrary, high expression level of CD44 in renal cancer and non-Hodgkin’s 
lymphoma is not always a relevant indicator [37].  
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The expression of a CD44 gene can result in multiple isoforms like the standard 
form (CD44s), variant form (CD44v) and other forms depending on the site of 
expression on the CD44 gene. When one of these isoforms bind to the so-called 
hyaluronic acid (HA) at the cellular membrane, the formed profile is called HA-
binding profile and can improve tumor growth (Fig. 2). However not all CD44 
receptors tend to bind to HA and accomplish this new structural formation. 
Studies on animal tissue have shown a high concentration of CD44 in tumor cell 
lines and more aggressive tumors forms [3, 30, 38]. In addition, CD44 is 
recognized to be actively involved in the tumor metastatic process, probably 
because of its rule in the lymphocytic migration process, especially the CD44v 
form that has metastatic properties [3, 30, 38]. 
 
A.3. Vitamin D, its active metabolite 1,25-dihydroxyvitamin 
D3, Vitamin D receptors and their role in malignancy 
A.3.1. Vitamin D and its active metabolite 1,25-dihydroxyvitamin D3 
(1,25-(OH)2D3) 
Vitamin D (Calcitriol) is represented by a group of fat-soluble secosteroids most 
importantly vitamin D3 (Cholecalciferol) and vitamin D2 (ergocalciferol). The most 
important physiological application of these compounds is to enhance the 
intestinal absorption of various elements like calcium, iron, magnesium, 
Figure 2: CD44s and CD44v 
cellular markers. The structure 
of the variant isoform (CD44v) 
and the standard isoform 
(CD44s). Hyaluronic acid binds 
itself to the ‘’N-terminal of the 
extracellular domain’’ resulting 
in the active form of CD44. CD44 
is important marker in cancers 
like Oral squamous cell 
carcinoma, head and neck 
cancer, breast cancer etc.. CD44v 
isoform is believed to have 
neoplastic activities Modified 
from [3] 
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phosphate and zinc. Many studies have shown the importance of this vitamin in 
preventing some bone diseases such as rickets, as well as its need for proper 
muscular function and its role in maintaining proper bone mass, in which 
inadequate vitamin D levels may lead to elderly osteoporosis. Furthermore, other 
studies suggested the importance of vitamin D in the prevention of type 1 
diabetes mellitus (with controversial evidence), hypertension as well as various 
common cancers. Vitamin D synthesis is mainly cutaneous, where sunlight-
exposure mainly to ultraviolet-beam (wavelengths of 290-315 nm) irradiation is 
the primary source. Mostly, dietary sources of vitamin D are less relevant [39].  
 
1,25-dihydroxycholecalciferol (synonyms are 1,25-dihydroxyvitamin D3 and 1α 
25-dihydroxyvitamin D3 also abbreviated in 1,25-(OH)2D3) is an active hormonal 
metabolite of vitamin D. Its structural form consists of three hydroxyl groups [40] 
(Fig. 3). 1,25-(OH)2D3 is produced in the kidney, keratinocytes 1,25-(OH)2D3, 
macrophages and other tissues like breast, prostate and colon cells. 1,25-
(OH)2D3 synthesis is resulted from the hydroxylation of 25-hydroxycholecaliferol. 
One of the main functions of 1,25-(OH)2D3 is to increase the absorption of calcium 
in the intestine by mediating the biochemical interactions for this process [41]. 
Aside from controlling calcium absorption and homeostasis by interacting with its 
specific receptor in the target tissue cytoplasm, 1,25-(OH)2D3 is widely 
recognized to be the hormonal form of vitamin D responsible for all its functions 
[42-45].  
 
 
 
 
Figure 3: Organic structure of 1,25-
dihydroxycholecalciferol Other scientific names include 
1,25-dihydroxyvitamin D3 (Abbreviated 1,25-(OH)2D3) 
which is commonly known as Calcitriol. 
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A.3.2. Antineoplastic activities of vitamin D, its active metabolites like 
1,25-(OH)2D3 and vitamin D analogues 
In the past decades, many researchers studied the role of vitamin D and its 
metabolites, mainly 1,25-(OH)2D3, and its implications on cancer prevention, 
development, pathogenesis and treatment. The essential vitamin D role in cell 
growth maintenance and regulation, the inhibition of proliferation and 
differentiation induction is well established in many researches [39, 46-50]. Other 
studies provided evidence that 1,25-(OH)2D3 can prevent cancer through the role 
of cell growth maintenance [46, 49, 51, 52]. This mode of action is explained as 
1,25-(OH)2D3 reduces angiogenesis, increases cellular apoptosis of cancer cells, 
as well as reduces cellular proliferation, and metastasis [46, 49-51, 53-60]. In 
addition, vitamin D analogues like paricalcitol is known to have anticancer action 
against myeloid leukemia, myeloma, and colon cancer cells [61]. For the first 
time, in a study on human melanoma cells Colston et al. established that 1,25-
(OH)2D3 successfully inhibited the growth of tumor cells and that the “time of 
malignant melanoma cells” was doubled after incubation with the hormone which 
confirms that melanoma cells are responsive to the hormone in vitro [62]. Later, 
the report of Miyaura et al. concluded that another role of 1,25-(OH)2D3 in 
leukemia cancer cells HL60 is to be added, where vitamin D is involved in cell 
growth and differentiation of this type of cancer cells. The presented effect was 
the induction of the differentiation of human promyelocytic leukemia into mature 
myeloid cells (myelocytes, metamyelocytes and mature granulocytes). For this 
function, 1,25-(OH)2D3 was the most potent vitamin D metabolite [63]. In the same 
year, Abe et al. confirmed the presence of vitamin D3 action on bone marrow cells 
and provided evidence for the differentiation of myeloid leukemia cells (M1 cells) 
into macrophages [64]. Another study described the mechanism of proliferation 
inhibition of leukemic NCI-H929 cells by Vitamin D3 analog [65]. Other than their 
role in leukemia, 1,25-(OH)2D3, also through its antiproliferative activity, found to 
be involved in inhibiting other cancers [51].  
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Breast cancer risk and lower levels of vitamin D are proportionally correlated in 
white women [66]. In a study on women in a region of high solar radiation, the 
reduction in breast cancer risk in 25% is noted and is associated with high vitamin 
D exposure [67]. In addition, it is found that a novel Gemini vitamin D analogue 
(BXL0124) was able to repress CD44 expression in vitro and in xenograft tumors 
inhibiting breast cancer cells [68].  
 
In brain cancer, 1,25-(OH)D3 proved to have cytotoxic effects on rat as well as 
human glioma tumor cell lines and successfully induced cellular death in the study 
of Naveilhan et al [69]. In prostate cancer, the antineoplastic antiproliferative 
responses of 1,25-(OH)2D3 through multiple mechanisms in human prostate 
cancer cell lines were also reported [70-72]. It is also concluded that prolonged 
insufficient vitamin D intake might increase the risk of prostate cancer. Therefore, 
inducing the synthesis of 1,25-(OH)2D in the prostate may decrease the risk of 
developing prostate cancer [70, 73]. 
 
In colorectal cancer, according to epidemiological studies, 1,25-(OH)2D3 
deficiency is associated with an more risk of colon cancer [74]. Palmer et al. 
Found 1,25-(OH)2D and other non-hypercalcemic Vitamin D analogues to be 
potential anticancer agents as they induced the differentiation of human colon 
carcinoma cells [75].  
 
In head and neck SCC, a study on a hamster buccal pouch with SCC found that 
the administration of systemic vitamin D3 aided in delayed carcinogenesis [76]. 
It was also shown that treating HNSCC with 1,25-(OH)2D3 promoted the 
maturation of dendritic cells and reduced the anti-immune cellular activity of 
CD34+ cells [77], which are known to negatively affect the cancer prognosis and 
increase its recurrence [78, 79]. Moreover, EB1089, a vitamin D3 analogue, can 
completely inhibit the growth of human laryngeal squamous cell carcinoma cells 
[80]. With less hypercalcemic activity, vitamin D analogues are found to induce 
G0/G1 cell cycle arrest when they or an active 1,25-(OH)2D3 targeted the cell 
cycle protein p21 responsible for this action [81]. Other studies on the 
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antineoplastic activity of Vitamin D and its derivatives like EB 1089 on HNSCC 
supported the claims about their preventive and therapeutic value [82, 83]. Also, 
the in vitro growth-inhibitory action in various OSCC after the administration of 
1,25-(OH)2D3 have been recently proven [84].  
A.3.3. Vitamin D receptor and VDR expression in tumor cells of 
various cancers 
Vitamin D receptor (VDR) is one of the nuclear receptor members of transcription 
factors family which is also known as NR1I1 (nuclear receptor subfamily 1, group 
I, member 1) [85]. The activation of VDR leads to the formation of “heterodimer 
with the retinoid-X receptor” that bind to the hormone response elements on DNA 
leading to the production of specific gene products through the known DNA 
expression process. VDR is also involved in “microRNA-directed 
posttranscriptional mechanisms”. [86].  
 
In the earlier mentioned study of Kumagai et al., VDR is found to mediate the 
action of anticancer Vitamin D and its analogues in myeloid leukemia, myeloma 
and colon cancer cells [61]. In addition, in a study on human melanoma cells, 
Colston et al., observed 1,25-(OH)2D3 receptors that were similar to normal well 
characterized receptors in 1,25-(OH)2D3 target organs. [62]. Later, Tanaka et al 
demonstrated the growth inhibition in mouse and human leukemic cells where 
VDR was expressed and led to the differentiation stimulation of leukemia cells 
(M1 cells) into mature macrophages among cells which are exposed 1,25-
(OH)2D3 [87].  
 
In breast cancer, Eisman et al. Made the first evidence of the presence of low-
capacity binding protein specific for 1,25-(OH)2D, which was found in cloned 
human breast cells. His study discussed its relevance to developing bony 
complications and the implication of these findings on tumor behavior [88]. Later, 
other studies confirmed the antiproliferative properties of 1,25-(OH)2D3 causing 
lower tumor cells activity and reduction of cell growth in breast cancer cells in 
relation to the high presence of VDR in cancer cell lines [89-93].  
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In head and neck squamous cell carcinoma, the 1,25-(OH)2D3 receptor mediated 
inhibition of neoplastic cellular growth is already demonstrated. In addition, it was 
found that this action of the hormone is dose-dependent and leads to down-
regulation of DNA synthesis and a reduction in cell numbers [94]. 
Aim of the study 
[13] 
 
B. Aim of the study 
B.1. Rational of the study 
The association between putative CSC compartment and VDR expression in 
CD44+ breast cancer has already been demonstrated [68]. However, this is the 
first study to assess this link in putative CSC compartment of OSCC. The 
treatment of OSCC with the aid of nontoxic endocrine cancer therapy has not yet 
been intensively discussed, which also mandates further investigations of VD, its 
analogues and their therapeutic value.  
B.2. Specific aims of this study 
1. To analyze the expression of VDR in OSCC as well as in normal mucosal 
tissue. 
2. To identify the relation between VDR expression and tumor relapse. 
3. To evaluate whether oral tissue may be a new potential target for biologically 
active 1,25-(OH)2D3 or its analogues, and to discuss their potency. 
4. To evaluate whether biologically active 1,25-(OH)2D3 or its analogues are 
helpful in guiding supportive treatment of patient with OSCC in accordance 
with the “carcinogenesis model based on putative CSC hypothesis” [30, 68]. 
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C. Materials and methods 
C.1. Patients and Tumor Specimen 
We did a retrospective review of 191 patients’ records after a primary radical R0 
tumor resection in the Department for Oral and Maxillofacial Surgery, University 
Hospital Tuebingen, over a period of ten years as well as 10 healthy individuals 
with normal oral mucosa tissue [1, 2]. Samples of patients with non-resectable 
disease, inadequate follow-up data as well as patients with preoperative 
antineoplastic radio- or chemotherapy were not included in the study [1, 2]. The 
specimens used in this study were retrospectively retrieved from the pathology 
archives, in which histopathological diagnostic conformation of squamous cell 
carcinoma was carried out by the Department of Pathology, University of 
Tuebingen. After routine histopathological work-up, specimens were formalin-
fixed and paraffin embedded tissues [1, 2]. Experienced pathologists have 
selected the paraffin-embedded tumor blocks and done the routine 
Haematoxylin-Eosin (H.E) stained sections. 
The study was approved by the local ethics committee [1, 2]. For every specimen 
and prior to surgical resection, an informed consent from the patients was 
obtained. We depended on the local tumor registry to get the follow-up data of 
our patients [1, 2]. The records of last follow-up were reviewed from the last recall 
in the outpatient department or the date of loco-regional recurrence or cancer 
specific death, respectively [1, 2]. Tumor and patient characteristics are 
summarized in Table 1. Intensive histopathological assessment was carried out 
blind to the prior histopathology report [1, 2]. Microscopic slides were prepared 
after cutting a 2μm thickness tissue-section from (FFPE) samples with a 
microtome and then were fixed on microscopic slides using warm water. [1, 2]. 
Tumor staging was carried out according to the Union for International Cancer 
Control (UICC) and the American Joint Committee of Cancer (AJCC) regulations 
of 2010.  
Materials and methods 
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Table 1: Clinicopathological characteristics and prognostic factors of 191 patients with OSCC of low and high VDR 
expressers. Cutoff value for VDR expression was determined by Receiver Operating Characteristics (ROC) analysis [1, 
2]. 
Characteristics 
 
Number of Patients 
 
p-value 
 Total 
n=191 
VDR expression 
Low (≤39%) 
n=136 (71%) 
VDR expression 
High (>39%) 
n=55 (29%) 
 
Age (y)    0.9286 
<60±11.8 93 (48.7%) 66 (71%) 27 (29%)  
≥60±11.8 98 (51.3%) 70 (71%) 28 (29%)  
Gender    0.6394 
Male 145 (75.9%) 105 (72%) 40 (28%)  
Female 46 (24.1%) 31 (67%) 15 (33%)  
Site distribution of OSCC    0.8589 
Lips  11 (5.8%) 9 (82%) 2 (18%)  
Tongue 42 (22.0%) 30 (71%) 12 (29%)  
Floor of the mouth 84 (44.0%) 59 (70%) 25 (30%)  
Palate 17 (8.9%) 10 (59%) 7 (41%)  
Buccal mucosa 10 (5.2%) 6 (60%) 4 (40%)  
Alveolar ridge 27 (14.1%) 22 (81%) 5 (19%)  
Histological Grading    0.6066* 
G1 50 (26.2%) 36 (72%) 14 (28%)  
G2 125 (65.4%) 90 (72%) 35 (28%)  
G3 15 (7.9%) 10 (75%) 5 (25%)  
G4 1 (0.5%) 0 (0%) 1 (100%)  
Depth of invasion    0.1834** 
pT1 75 (39.3%) 50 (67%) 25 (33%)  
pT2 52 (27.2%) 36 (69%) 16 (31%)  
pT3 18 (9.4%) 16 (89%) 2 (11%)  
pT4 46 (24.1%) 34 (74%) 12 (26%)  
Cervical lymph node metastasis    0.9442 
pN0 133 (69.6%) 94 (71%) 39 (29%)  
pN1-3 58 (30.4%) 42 (72%) 16 (28%)  
UICC stage    0.3386*** 
UICC I 57 (29.8%) 38 (67%) 19 (33%)  
UICC II 42 (22.0%) 29 (69%) 13 (31%)  
UICC III 34 (17.8%) 26 (76%) 8 (24%)  
UICC IV 58 (30.4%) 43 (74%) 15 (26%)  
Locoregional recurrence    0.0002 
No 140 (73.3%) 89 (64%) 51 (36%)  
Yes 51 (26.7%) 47 (92%) 4 (8%)  
Abbreviations: y, years; G, grading; UICC, Union for International Cancer Control; *G1/2 vs. G3/4; 
**pT1/2 vs. pT3/4; ***UICC I/II vs. UICC III/IV. 
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Tumor grading was performed depending on the World Health Organization 
(WHO) criteria [95]. The information about tumor characteristics and UICC stage, 
pT-categories, pN-categories, pM-categories, lymph nodes infiltration as well as 
residual tumor status were then gathered [1, 2]. In addition, tumor size and site 
distribution along with other patients’ characteristics like gender, age, personal 
history and habitual history were considered [1, 2]. All this data was used to 
construct a Microsoft Excel © database [1, 2]. After tissue fixation, tissues surgical 
resection margins status was determined in the final histopathological evaluation, 
in which close margins were deemed positive in all analyses [1, 2]. However, 
margins that were greater than or equal to 10 mm from resection margin were 
considered as negative [1, 2]. 
C.2. Staining procedure and quantitive 
immunohistochemistry 
Unconjugated specific VDR, CD44, Ki-67, and isotype control antibodies were 
purchased for immunohistochemical analysis from Santa Cruz Biotechnology 
(CA, USA, mouse anti-human VDR mAb, D-6 sc-13133, dilution: 1:50), BD 
Pharmingen (Heidelberg, Germany, mouse anti-human CD44 mAb, 550392, 
dilution: 1:50), and Novocastra (Newcastle, UK, mouse anti-human Ki-67 mAb, 
NCL-Ki67-MM1, dilution: 1:50) [1, 2]. Moreover, we purchased VDR clone from 
LifeSpan Biosciences (Eching, Germany, rabbit anti-human VDR pAb, LS-B2976, 
dilution: 1:100), in order to confirm the VDR expression stained with anti-VDR 
mAb from Santa Cruz in a selection of 30 cancer samples and BICR cancer cell 
lines and we used this clone for double labeling experiments [1, 2].  
Then, series of steps followed to carry out the Pretreatment through slide fixation, 
deparaffinization, rehydration, heat-induced epitope retrieval of FFPE slides 
blocking to accomplish the immunohistochemical single staining [1, 2]. Briefly, 2 
μm thickness tissue sections were cut on a microtome from paraffin blocks and 
mounted on adhesive microscope slides [1, 2]. Serial sections were 
deparaffinized using xylene and ethanol and rehydrated in water [1, 2]. Using 
citrate buffer pH 6.0, Heat induced epitope retrieval (HIER) was performed [96], 
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[1, 2]. Alkaline phosphatase (AP) conjugated AffiniPure donkey-anti-mouse IgG, 
at 1:200 dilution (Jackson ImmunoResearch Laboratories Inc., Suffolk, England) 
was used as “a secondary antibody for immunohistochemical double staining” of 
CD44 [1, 2]. A horseradish peroxidise (HRP) conjugated AffiniPure donkey-anti-
rabbit IgG (Jackson ImmunoResearch) was used as a secondary antibody for 
VDR (LifeSpan Biosciences, rabbit anti-human VDR pAb, LS-B2976) in dilution 
at 1:200. Fluoresceinisothiocyanate (FITC) conjugated AffiniPure donkey-anti-
rabbit IgG in dilution at 1:200 (Jackson ImmunoResearch) was used as a 
secondary antibody for immunofluorescence double staining of VDR [1, 2]. A 
Cy3-conjugated AffiniPure donkey-anti-mouse IgG (Jackson Immuno- Research) 
in dilution at 1:200 was used as a secondary antibody for Ki-67[1, 2]. Cell counting 
was carried out for the immunohistochemistry quantification [1, 2]. Results were 
described in percentages where a number of positive tumor cells within 100 given 
tumor cells were counted [1, 2]. Results with less than 10% positive cells were 
considered negative [1, 2]. ImageJ software (http:/rsbweb.nih.gov/ij/) coupled 
with immunomembrane plug-in (http://imtmicroscope.uta.fi/immunomembrane) 
was used to have computer-assisted semi-quantitative analysis in order and to 
assess the quantification of VDR immunoreactivity in microscopically acquired 
JPEG images of OSCC samples [1, 2]. Staining completeness (0–10 points) and 
intensity (0–10 points) were added for a combined score (0–20 points) [1, 2]. To 
assess precision (reproducibility/ repeatability) of computer-assisted semi-
quantitative analysis, 5 images per VDR positive sample slide showing 
representative tumor areas were acquired using 20x objectives [1, 2]. Canon 
camera (Krefeld, Germany) was used to analyze produced pictures. Microsoft 
Office Picture Manager © was used to import the photographed images [1, 2].  
C.3. Cell Culture 
VDR expression was analyzed in cells (1x104) from the OSCC cell lines BCR3 
and BICR56 (American Type Culture Collection, ATCC) in cytospins as positive 
control of VDR expression by cancer cells [1, 2]. Preparation and staining of 
cytospins was performed [1, 2]. We analyzed VDR expression in BCR3 and 
BIC56 cell lines from patients with OSCC and healthy individuals on protein and 
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mRNA level in cytospins as positive control for the case of VDR expression [1, 
2]. Cytospins were fixed in acetone then dried for 10 minutes [1, 2]. Rehydration, 
blocking and the staining procedure steps followed as for immunohistochemistry 
of FFPE sections [96]. We cultured BICR3 and BICR56 cells in DMEM F-12 
medium (Invitrogen, Belgium) containing 10% FCS (Sigma-Aldrich, Germany), 
1% fungicide, and penicillin/streptomycin (Biochrom, Germany) at 37°C and 5% 
CO2  [1, 2]. 
C.4. Immunohistochemical and immunofluorescent double 
labeling experiments 
For VDR-CD44 expression in FFPE tissue and OSCC cell lines (BICR3, BICR56), 
the sequential immunohistochemical (IHC) double staining (co-expression) was 
analyzed [1, 2]. For VDR- Ki-67 expression in FFPE tissue, the sequential 
immunofluorescence double labeling (co-expression) was analyzed [1, 2].  
 
“Slides were incubated with the primary CD44 antibody (mouse mAb) or control 
antibody overnight at 4°C in a humidified chamber and with secondary AP-
conjugated antibody for 30 minutes at room temperature in a humidified chamber 
followed by 20 minutes of incubation with Fast Red (Biogenex, San Ramon, USA) 
to perform the IHC double staining. Subsequently, the slides were then incubated 
with the second primary VDR antibody (rabbit pAb) or control antibody overnight 
at 4°C in a humidified chamber and with a secondary HRP-conjugated antibody 
for 30 minutes at room temperature in a humidified chamber” [1, 2]. Then slides 
were incubated for 5 minutes with 3,3'-Diaminobenzidine (DAB, Biogenex). 
Counterstaining with Haemalaun and mounting with Glycergel (Dako, Hamburg, 
Germany) was then performed [1, 2].  
 
Immunofluorescence double labeling was performed after incubating the slides 
with a primary VDR antibody (rabbit pAb) or control antibody overnight at 4°C 
using a humidified chamber and then with a secondary FITC-conjugated antibody 
for 30 minutes at room temperature also in a humidified chamber [1, 2]. 
Subsequently, the slides were then incubated with the second primary Ki-67 
antibody (mouse mAb) or control antibody overnight at 4°C using a humidified 
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chamber and with secondary Cy3-conjugated antibody for 30 minutes at room 
temperature in using a humidified chamber [1, 2]. Counterstaining of the slides 
with DAPI (4’,6-Diamidino-2-phenylindoldihydrochloride, Sigma-Aldrich, 
Taufkirchen, Germany) then covering with Polyvinyl-alcohol mounting medium 
(DABCO, Sigma-Aldrich) was performed [1, 2]. Microsoft Office Picture Manager 
© was again used to import the photographed images [1, 2]. 
 
C.5. Real-time quantitative reverse transcription-PCR 
analysis (RT-PCR) 
To measure gene expression of VDR by RT-PCR, cellular RNA was extracted 
and cDNA synthesis was performed from OSCC cell line (BICR3, BICR56) and 
FFPE tissue [1, 2, 97]. RNA measurement was carried out by measuring the 
absorbance at 260 nm. The purity and contamination absence of total RNA was 
confirmed with a ratio of 260:280 nm of the total RNA [1, 2]. Normal matched 
human mucosal cDNA was purchased from BioChain (Hayward, CA, USA) as 
control [1, 2]. Relative quantification and cDNA quality (integrity) was controlled 
using the reference genes Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and beta-actin [1, 2]. Commercial primer kits (VDR, GAPDH, beta-
actin) were purchased from Search LC (Heidelberg, Germany) [1, 2]. mRNA 
expression quantitation was determined by establishing RT-PCR with the 
LightCycler System (Roche Applied Science, Mannheim, Germany), [1, 2]. The 
RT-PCR for GAPDH and VDR was carried out by using a volume of 20 µL which 
contains 2 µL cDNA, 2 µL primer mix (commercial primer kits from Search LC, 
Heidelberg, Germany), 2 µL DNA Master Sybr Green I mix (Roche Applied 
Sciences, Mannheim, Germany) and 14 µL DEPC treated water [1, 2]. Target 
DNA was amplified during 35-38 cycles of 95°C for 10 seconds, 68°C for 10 
seconds and 72°C for 16 seconds with temperature transition rate of 
20°C/second for each cycle and secondary temperature of 58°C with a step size 
of 0.5°C [1, 2]. To identify specific reaction products, Melt-curve analysis was 
used [1, 2]. The relative quantification value, fold difference, is expressed as 
2−ΔΔCt [1, 2]. More specifically, in order to separate  unspecific primer dimers and 
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specific PCR products, melting curve analysis at 95 °C 0 seconds, 58 °C 10 
seconds and 95 °C 0 seconds was achieved [1, 2]. With the aid of specific 
commercial primer kits (Search LC, Heidelberg, Germany), the transcript levels 
of VDR and housekeeping GAPDH for each sample were determined [1, 2]. 
Results were then calculated in the form of ratio of target vs. housekeeping gene 
transcription [1, 2, 98].  
C.6. Western blot analysis and densitometric quantification 
Western blot analysis was used to confirm VDR antibody specificity [1, 2]. Protein 
extraction from OSCC cell lines BICR3 and BICR56 was performed [1, 2, 99]. As 
a control, normal human mucosal protein purchased from BioChain (Hayward, 
CA, USA) was used [1, 2]. For this analysis, cells were harvested on ice. Cells 
were then centrifuged and then dissolved in 60 μl lysis buffer [1, 2]. Cells were 
then incubated overnight at temperature of -70°C [1, 2]. The removal of cell debris 
was done by centrifugation [1, 2]. To measure the protein concentrations of the 
supernatants, colorimetric assay (RD DC Protein Assay, Bio Rad, Germany) was 
used according the manufacturer’s manual [1, 2, 99]. After that, a total of 100μg 
of denaturized cell lysate from the cellular extracts were separated by SDS-PAGE 
(10%) and transferred onto nitrocellulose membranes after the addition of 
reducing Laemmli sample buffer [1, 2, 100]. Using monoclonal mouse anti-human 
VDR (Santa Cruz Biotechnology, mouse anti-human VDR mAb, D-6 sc-13133, 
dilution: 1:100) and monoclonal mouse anti-human GAPDH (Abcam, Cambridge, 
UK, ab8245, dilution: 1:5000) specific primary antibodies incubation overnight at 
4°C, the membranes were then analyzed [1, 2]. HRP-conjugated goat anti-mouse 
secondary antibody (Santa Cruz Biotechnology, USA) was used to detect the 
binding of the primary antibodies [1, 2]. Specific bands showing VDR and GAPDH 
proteins were visualized by the “enhanced chemiluminescence method” (GE 
Healthcare, Freiburg, Germany) [1, 2]. To quantify VDR intensity of western blot 
bands, we used an “automated densitometric quantification digitizing system” 
(UN-SCAN-IT Gel © software, version 6.1, Silk Scientific Inc., Utah, USA) [1, 2]. 
JPEG in 8-bit gray scale format at 600 dpi were produced by scanning the 
developed films followed by the measurement of the pixel intensities within a 
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band[1, 2]. Quantification of western blot bands with the segmental analysis 
method was done with the UN-Scan-it © software [1, 2]. The constant pixel 
measurement was assured by Clone drawing mode which was used to perform 
pixel summation of individual segments [1, 2]. Pixel intensities correction was 
performed in the background [1, 2]. Digitized gel data (pixel total) were imported 
into an Excel database (Excel ©, Microsoft ®) [1, 2]. 
C.7. Statistical analysis  
For the statistical analysis, MedCalc © Software, Version 12.3.0 (Mariakerke, 
Belgium) was used [1, 2]. To calculate Disease-specific survival (DSS), duration 
from the time of tumor resection until obvious loco-regional recurrence or tumor 
conditional death respectively has been considered [1, 2]. To assess differences 
in the DSS for patients who received successful (R0) curative surgical resection 
for OSCC, patients were classified into VDR high expressers (VDR high) and 
VDR low expressers (VDR low) [1, 2, 101]. ROC analysis was performed in order 
to determine the best cutoff range for OSCC recurrence group screening VDR 
expression [1, 2]. Quality measurement of VDR expression, area under the curve 
(AUC) analyzed [1, 2]. The value of the “highest diagnostic average of sensitivity 
and specificity” (highest diagnostic accuracy) was determined as the cutoff point 
and was calculated at 39% VDR expression in correspondence with the highest 
Youden index [1, 2]. To test for a normal distribution of the data, the D’Agostino-
Pearson test was performed [1, 2]. To estimate the DSS times, the Kaplan-Meier 
method was used then it was compared using the log-rank test [1, 2, 102, 103]. 
Using the Cox Proportional Hazards Model, multivariate analyses were 
performed [1, 2]. The resulted significant parameters on univariate analysis were 
included [1, 2]. 95% Confidence Interval (CI) was provided for hazard ratios (HR) 
of variables that may influence survival status in univariate and multivariate 
analysis [1, 2]. To assess the two categorical variables relation, Chi-Square test 
(χ2) and Fisher's exact test were used [1, 2]. The accuracy was considered as 
‘’the degree of closeness of measurements of a quantity to that quantity's actual 
value’’ [1, 2, 100, 104]. Non-parametric Kendall´s tau (т) correlation coefficient 
measurement was performed in order to assess the accuracy between the two 
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quantification methods of immunohistochemical analysis taking in consideration 
“the manually counted percentages of positive tumor cells within 100 counted 
tumor cells vs. combined score of computer-assisted semi-quantitative analysis” 
[1, 2, 100, 104]. The “non-parametric Spearman Rho rank correlation coefficient” 
was used to perform Correlation analysis of the VDR count (%) with Ki-67 count 
(%) [1, 2]. Pearson's correlation (Rr) index was used to measure the co-
localization parameter of immunofluorescent double labeling [1, 2, 100, 104]. 
Significant P-value considered being p < 0.05 in which all P-values were 2-sided 
[1, 2]. 
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D. Results 
In order to assess the accuracy between our two quantification methods of 
immunohistochemical analysis, a preliminary study was carried out in which a 
significant correlation between the first and second assessment was found 
showing VDR expression results of: т = 0.979, p < 0.0001, 95% CI 0.972 to 0.984 
[1, 2]. 
D.1. There is no association between VDR expression and 
clinicopathological characteristics of OSCC 
In normal oral mucosa samples (n=9/10), VDR was relatively not highly detected 
in the basal layer cells in healthy oral squamous epithelium [1, 2]. In stromal cells, 
VDR expression was very weak but considerably associated with present cancer 
cells [1, 2]. Clinicopathological characteristics and prognostic factors of 191 
patients with OSCC measured by ROC analysis are summarized in table 1. More 
importantly, VDR expression within the tumor cells was found in 50% of the 
patients with OSCC (n = 96/191). The mean VDR expression rate in positive 
tumor samples was 47%, 95 CI for the mean 42.6 to 50.7%, lowest value was 
12% and highest value was 87% [1, 2]. However, no associations between VDR 
expression and clinicopathological characteristics were found [1, 2]. Using area 
AUC analysis, 39% VDR expression cutoff point of VDR expression led to the 
optimal sensitivity and specificity for the diagnosis of patients with recurrence 
(AUC: 0.638, p = 0.0006, 95% CI 0.566 to 0.706) (Fig. 4) [1, 2]. In 29% of the 
patients (n = 55/191), high VDR expression was analyzed [1, 2]. VDR with CD44 
expression were primarily found in the epithelial basal layer cells, which were 
shown in representative images of Immunohistochemistry of OSCC serial 
sections (Fig. 5a,c) [1, 2]. By staining the OSCC cell lines (BICR3 and BICR56) 
in cytospins as control measure, positive results of cancer cells VDR expression 
pattern was confirmed (Fig. 6a-c) [1, 2]. 
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Figure 4: Receiver operating characteristics 
(ROC) curve for VDR expression in OSCC patients 
[1, 2]. For the measurement of the cutoff point, 
sensitivity (the true positive rates) are plotted in 
function of false positive rates (100-specificity): 
the arrow represents the cutoff value with 
highest diagnostic accuracy of VDR expression 
analyzed at 39% for the diagnosis of recurrent 
group. (Sensitivity= 94.12 %, 95 % CI 83.8–98.8 
%; specificity= 36.43 %, 95 % CI 28.5–45.0 %). 
Dotted lines show 95 % CI [1, 2, 104]. 
 
 
 
D.2. The confirmed correlation between CD44+ cancer cells 
and VDR expression in OSCCC cell lines 
OSCC serial tissue sections and cell lines were stained using 
immunohistochemical double-staining experiments to investigate, whether 
CD44+ CSCs are associated with VDR expression or not [1, 2]. Dominant 
populations of CD44+/VDR+ tumor cells in the epithelial basal layer of OSCC 
tissues were found (Fig. 5e), similar to what was suggested by OSCC 
immunohistochemical stained serial sections with single staining procedure. (Fig. 
5a, c) [1, 2]. Another evaluation of BICR3 and BICR56 in OSCC cell lines and 
immunohistochemical double staining confirmed co-expression of CD44+/VDR+ 
(Fig. 6d) [1, 2].  
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Figure 5: Immunohistochemical single staining (VDR, CD44) and double staining (VDR with 
CD44) of serial sections in OSCC (magnification ×200-fold) [1, 2]. Note the formation of 
epithelial cells within epithelial layer(Asterisks). The area of interest is showed in the small 
box. Slides a, b represents images of VDR expression and CD44 in slides c, d VDR with CD44 
single and immunohistochemical double staining in slide e. Slide f shows IgG control with no 
staining. In slides b, d: the staining parts of ‘’computer-assisted semi-quantitative analysis’’ 
on VDR+ and CD44+ OSCC cells is shown, where red labels b, d represent heavy or complete 
staining and green labels represent weak or weaker staining. In slides a, e, brown chromogen 
color (3,3ʹ-diaminobenzidine) indicates positive VDR and in slide c indicates CD44 staining. 
In slide e, red chromogen color (Fast red) of double stained tumor cells shows CD44+ cells 
and the blue color indicates the nuclear counterstaining by hematoxylin. The strong presence 
of VDR and CD44 expression in the epithelial basal layer cells is noted [1, 2]. 
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Figure 6: VDR expression within BICR3 and BICR56 OSCC cell lines[1, 2]. Slides a-d represent the 
Immunocytochemical single and double staining of VDR expression. Slides e, f represents Western blot analysis of 
VDR expression. Slide a shows images of IgG control. Slide b shows images of VDR expression in BICR3 cell lines. Slide 
c shows images of VDR expression in BICR56 cell lines. Slide d shows images of immunocytochemical double staining 
of VDR in brown areas (3,3ʹ-diaminobenzidine) show with brown arrows. CD44 immunocytochemical double staining 
in red  areas (fast red) showed with red arrows. Original magnification is ×400-fold. In slide e, the specificity of 
immunohistochemical staining and increased VDR expression in comparison to normal tissue was confirmed by 
Western blot of VDR in BICR3 and BICR56 OSCC cell lines. The graph f represents a densitometric quantification of 
Western blot protein bands in pixel total VDR expression in BICR3 and BICR56 and normal tissue. As predicted, the 
detected molecular weight of VDR is in accordance with the predicted molecular weight of 50 kDa. GAPDH (loading 
control), which is detected as a band of approximately 35 kDa [1, 2]. 
D.3. VDR specificity is confirmed by western blot analysis 
The performed western blot expression in OSCC cell lines (BICR3 and BICR56) 
confirmed the specific results of the VDR immunohistochemical staining [1, 2]. 
That revealed increased VDR in OSCC cell lines compared to normal tissue [1, 
2]. The detected molecular weight of VDR (50 kDa) matched the predicted 
molecular weight [1, 2]. The molecular weight of GAPDH, which we considered 
as control, was detected on approximately 35 kDA (Fig. 6e) [1, 2]. Compared to 
normal tissue, densitometric analysis allowed for positive quantification of VDR 
western blot protein bands (pixel total) in both BICR3 and BICR56 OSCC cell 
lines [1, 2].  
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D.4. VDR+ tumor cells and proliferating (Ki-67+) OSCC cells 
are inversely correlated 
All OSCC tissue samples (n = 191) were analyzed for Ki-67 immunoreactivity in 
tissue serial sections in order to evaluate weather VDR+ tumor cells associated 
have anti-proliferating properties or not. We found that Ki-67 expression in OSCC 
had a weak but significant inverse correlation (r = -0.4308, p < 0.0001) with the 
expression of VDR. This analysis resulted from “quantified immunohistochemical 
single staining results of VDR with proliferating tumor cells (Ki-67+)” (Fig. 7a) [1, 
2]. The results of the immunohistochemical single staining procedure in FFPE 
slides were confirmed by the representative double-immunofluorescent staining 
of VDR with Ki-67 [1, 2].  
 
 
Figure 7: Correlation and co-expression analysis of VDR with Ki-67. Calibration bar represents 25 μm[1, 2]. 
Immunofluorescent double staining of VDR with Ki-67 confirms the immunohistochemical single staining results in 
OSCC FFPE tissues. Slide a shows the correlation analysis of VDR with Ki-67 from quantified immunohistochemical 
single staining results of VDR (measured in %) in OSCC FFPE tissues with proliferating cells (Ki-67 measured in %), Ki-
67 expression in OSCC had a weak but significant inverse correlation with the expression of VDR (r=−0.4308, 
p<0.0001). Slide b represents the Ki-67 expression (red, Cy), slide (c) represents VDR expression (green, FITC). Slides 
d, e shows the co-expression in OSCC FFPE tissues showing the majority of proliferating (Ki-67+) cancer cells without 
VDR expression (asterisks, merge). To adjust a better contrast, co-expression of VDR/Ki-67 is demonstrated with (left, 
slide d) and without (right, slide e) nuclear counterstaining (blue, DAPI). White dotted arrows point to areas of 
increased coexpression indicating that VDR expressing cancer cells are seldom strongly associated with proliferating 
cells but mainly detected without or with weak Ki-67 expression (white arrows). Co-localization parameter (merge, 
slides d, e) of Ki-67/VDR (red and green) measured by Pearson's correlation (Rr) index is analyzed at 0.08. FITC, 
fluoresceinisothiocyanate, Cy3, Cyanine 3 red, and DAPI 4ʹ,6-diamidino-2 phenylindoldihydrochloride [1, 2, 100].  
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D.5. VDR gene expression analysis 
Gene expression of VDR in OSCC cell lines BICR3 and BICR56 was assessed 
to confirm the results of the immunohistochemical staining [1, 2]. In comparison 
to normal tissue, VDR gene expression in OSCC tissues was increased [1, 2]. A 
3.34-fold and a 11.47-fold higher expression was shown by BICR3 and BICR56 
cell lines respectively, in comparison to normal tissue [1, 2]. A 3.9-fold higher 
expression was shown by the representative analysis of VDR gene expression in 
OSCC tissue [1, 2].  
D.6.  OSCC-VDR expression prognostic value 
Patients were divided into two groups (disease recurrence and absence of 
disease recurrence) in order to analyze the survival rates after successful (R0) 
surgical resection of OSCC [1, 2]. In univariate analysis of all (n=191) OSCCs, 
cervical lymph node metastasis (pN1-3, HR = 2.0010, 95% CI = 1.0411 to 3.8458, 
p = 0.0138) as well as depth of invasion (pT3/4, HR = 1.4689, 95% CI = 0.7706 
to 2.7999, p = 0.1903) and grading (G3/4, HR = 0.8641, 95% CI = 0.2893 to 
2.5813, p = 0.8052) were shown as unfavorable factors [1, 2, 100]. Patients were 
also divided into two groups according to the intensity of VDR expression (VDR 
low and VDR high expression) in order to analyze differences in tumor related 
survival dependent on VDR expression in OSCC [1, 2]. Worse survival was found 
in the group of low VDR expression in OSCC (VDR low: n=136, p < 0.0001, HR 
= 6.3220, 95% CI = 3.5557 to 11.2404) in compared to the group of patients with 
high VDR expression (Fig. 8a). Cox Proportional Hazards Model multivariate 
analysis showed low VDR expression and positive lymph node metastases as 
independent prognostic factors in all OSCCs samples (VDR low: Exp (b) 6.1791; 
95% CI of Exp (b) 2.2352 to 17.0823; p = 0.0005; (Fig. 8b). LN positive, pN1-3: 
Exp (b) 1.8998; 95% CI of Exp (b) 1.0764 to 3.3531; p = 0.0276) [1, 2]. 
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Figure 8: Survival curves of OSCC patients measured by VDR expression [1, 2]. Curve a: Kaplan–Meier curve shows 
survival for disease-specific survival (DSS) stratified by high VDR expression (black line) and low VDR expression 
(dotted line). Curve b: Cox regression curve shows survival for disease-specific survival (DSS) stratified by high VDR 
expression (black line) and low VDR expression (dotted line). Low VDR expression (n=136/191) in OSCC is found to be 
associated with poorer survival. DSS 1-, 3-, and 5-year survival rates (VDR high vs. VDR low) in univariate Kaplan- 
Meier survival curve (a) are 100 % vs. 97 %, 94 %, vs. 78 %, and 94 % vs. 65 %, respectively. The times of the censored 
data are indicated by short vertical lines. DSS 1-, 3-, and 5-year survival rates (VDR high vs. VDR low) in multivariate 
Cox regression (b) survival curve are 100 % vs. 99 %, 96 %, vs. 82 %, and 94 % vs. 65 %, respectively [1, 2]. 
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E. Discussion 
Vitamin D activities are known to be mediated by its active metabolite 1,25-
(OH)2D3 [42-45]. 1,25-(OH)2D3 mediate major cellular activities that can influence 
carcinogenesis in most body cancers. Among these activities inhibition of 
proliferation, induction of differentiation, as well as reduction of angiogenesis, and 
induction cellular apoptosis are most important for cancer therapy. [46, 49-51, 53-
60]. It is also suggested that Vitamin D can directly and indirectly play a role in 
overcoming the HNSCC immune suppressive activity, which is profound 
characteristic in this disease [105]. Moreover, the treatment with 1,25-(OH)2D3 
leads to stimulation of the infiltration of CD44+ and, in higher amount, CD8+ T 
cells, which in turn leads to lengthening the time to HNSCC tumor recurrence 
[106]. 1,25-(OH)2D3 is also, in a complex way, able to alter the balance of 
cytokines within HNSCC tumor cells [107].  
 
The involvement of VDR in cancers other than OSCC like breast cancer, myeloid 
leukemia, myeloma, colorectal cancer and head and neck cancer is in various 
studies well established (Bower, 1991;Colston, 1981; Colston, 1992; Eisman, 
1979; Frampton, 1983; Kornfehl, 1996; Kumagai, 2003; Lisse, 2013; M oore, 
2006; Tanaka, 1982; Vink-van Wijngaarden, 1996). In parallel to that, a recent in 
vivo and in vitro study, VDR expression has been found to be inversely correlated 
with CD44+ CSCs in breast cancer, meaning that VDR has performed a 
repressing activity on CD44+ CSCs [68]. However, no other studies on the role 
of VD and its receptor in OSCC have been performed yet, which is the main 
reason for conducting our study.  
 
As far as we know, this is the first report demonstrating VDR expression in 
association with OSCC prognosis. In this study, we analyzed VDR expression in 
191 OSCC samples within two cancer cell lines. In addition, we examined 10 
samples of normal oral mucosa. Specialized pathologists carefully selected all 
samples included in this study. Our study confirmed that VDR expression is 
present in both cancer and non-cancer tissue samples [1, 2]. VDR expression 
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was mainly restricted to the basal layer of normal oral mucosa as well as in OSCC 
tissue [1, 2]. Marked overexpression in human OSCC has been detected. 
Western blot an RT-PCR analysis confirmed VDR specificity [1, 2]. This study 
also revealed similar data to a report by Reichrath et al., in which predominant 
VDR expression within the basal cell layer of normal and SCC cells of cervix were 
noted. VDR up-regulation at protein level in cervical carcinomas cells in 
comparison to normal tissue was also observed in that study [1, 2, 108]. ROC 
analysis helped in identifying a cutoff value for subgroups in 
immunohistochemical analysis for tumor recurrence. Our finding supports the 
hypothesis that increased VDR expression may be associated with increased-
tumor specific survival amongst patients with high VDR expression compared to 
patients with a low VDR subgroup [1, 2]. However, no difference was detected 
concerning other the clinicopathological characteristics [1, 2]. Although CD44 
populations “may indeed harbor a subpopulation encompassing stem cells”, this 
alone does not appear to be an adequate marker for stem cells of normal oral 
mucosa [109].  
 
On the other hand, CD44 putative CSC marker in normal head and neck 
epithelium was investigated in various studies with differing results. For instance, 
one study suggested that CD44 might be expressed in normal oral epithelial stem 
cells, where isolated CD44 normal oral keratinocytes found to exhibit G2-block 
associated with apoptosis resistance. It was also suggested that targeting these 
G2 checkpoints proteins might deactivate these checkpoints making cells no 
more resistant to cellular apoptosis [110]. Another report by Prince et al. 
concluded that tumor subpopulation with increased tumorigenicity was isolated 
using CD44 expression in head and neck cancer [33]. Therefore, the use of CD44 
as a stem cell marker in normal tissue as well as in OSCC cancer stem cells may 
be rational due to its established relevance in breast cancer [33].  
 
VDR could “provide a novel molecular link between the physiologic mucosal stem 
cell niche and the cell-of-origin for OSCC” for the reason that OSCC can arise 
from physiologic mucosal stem cells [100, 111] that include CD44+ cell 
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populations [112]. Due to the lack of further in vitro and in vivo studies to show 
tumor development by colony and spheroid properties formation, our results 
describe VDR expression by CD44+ CSC. However, our observations may help 
to make more future explanations of tumor cells with stem cell properties. For 
tumor relapse and recurrence, hypothesis about a possible involvement of 
putative residual cancer stem cell compartments has been rising. Therefore, in 
order to understand this, our study emphasized on the “co-expression of putative 
CD44+ CSC with VDR expression in OSCC tissue and cancer cell lines”. Our 
analysis of immunohistochemical double staining experiment data 
(CD44+/VDR+), clearly showed a heavy co-expression of VDR+ with CD44+ 
cancer cells [1, 2]. In line with this finding, the earlier mentioned study of So et al. 
discussed a novel Gemini vitamin D analogue (BXL0124) that was able to repress 
CD44 expression in vitro and in vivo leading to inhibition of breast CSCs [68]. 
From a therapeutic point of view, the demonstrated increase of VDR content in 
OSCC lead us to hypothesize that putative CD44+ CSC in OSCC may be 
sensitive to endogenous or exogenous therapeutic 1,25-(OH)2D3. However, in 
this study, the functional roles of VDR in OSCCs are not to be concluded from 
our results [1, 2]. Although we know that high VDR expression is associated with 
increased overall survival rates in other cancers like in esophageal cancer [113], 
it is not yet known if VDR in OSCCs exhibit a mutational inactivation function 
leading to more expression [1, 2]. Other hypothesis is that tumor cells defective 
from VDR may tend to signal a feedback loop, which results in increased VDR 
expression and consequently more presence of VDR in OSCCs [114].  
 
The enhancement of VDR expression at the mRNA and protein levels in vitro by 
various cell types have been already demonstrated [115, 116]. However, Weise 
et al. found no change in VDRs mRNA levels after the administration of 1,25-
(OH)2D3, which leads to the conclusion that VDR protein level elevation is due to 
increased receptor protein lifetime and not directly induced by increased gene 
transcription [116]. Because of the ability of keratinocytes to hydroxylate vitamin 
D at the C-1 and C-25 positions [117], it can be concluded that keratinocytes are 
able to synthesize the biologically active 1,25-(OH)2D3, the vitamin D metabolite 
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responsible for almost all its activities [45]. However, OSCCs capability of 1,25-
(OH)2D3 synthesis is not yet known and needs to be further investigated. On the 
other hand, one can speculate that increased expression and volume of VDR on 
the mRNA and protein level may be the result of increased production of 1,25-
(OH)2D3 in these tumor cells. Moreover, it is also possible that VDR expression 
up-regulation in neighboring tumor cells may be due to cytokines and 
inflammatory peptides released from tumor-invading leucocytes as well as tumor 
cells [108].  
 
The higher the number of receptors, the higher the responsiveness of steroidal 
hormone [115]. Based on the suggestion that the biological effects of calcitriol 
and its analogs like cellular proliferation and differentiation in target cells are 
mediated by VDR [118], increased VDR expression and content in tumor cells 
(mainly CD44+ CSCs) may represent a point of weakness in tumor cells which 
could open the gate for another module of adjuvant antineoplastic treatment of 
OSCC [1, 2]. As indicated by our double labeling experiment (Ki-67/VDR+), the 
demonstrated increased VDR expression was inversely correlated with 
proliferating cancer cells. This finding may be possible due to the fact that VD 
poses anti-proliferating properties [1, 2, 94]. However, VDR expression could be 
determined by other different mechanisms, an interesting suggestion could be 
that VDR expression may be a function of the state of differentiation [1, 2]. The 
highest maximal ligand binding of VDR is in the early phase of cell growth. While 
studying human keratinocytes, Pillai et al. found that the number of VDR 
receptors have fallen as soon as cells differentiated, which decreased the 
influence of 1,25-(OH)2D3 on these cells. Thus, higher influence of 1,25-(OH)D3 
was more noted at the early stage of cellular differentiation [119].  
 
Although pre-treatment 1,25-(OH)2D3 dietary intake of HNSCC patient and 
vitamin D serum level may have no influence on disease outcomes [120], the 
findings of this study along with previous findings lead us to speculate that the 
therapeutic use of 1,25-(OH)2D3 or its non-hypercalcemic analogues as adjuvant 
chemopreventive therapy could be even more successful than targeting the vast 
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majority of cancer cells. This therapy could mainly be aimed to target adjuvant 
residual tumor cells [1, 2]. Some studies suggested that 1,25-(OH)2D3 could 
reduce tumor growth of HNSCC. For instance, on a study on hamsters with 
HNSCC, tumor cells of the buccal pouch responded positively with delayed tumor 
carcinogenesis [76]. Aside from this, levels of immunosuppressive CD34+ cells 
in HNSCC were reduced in response to treatment with Vitamin D, which also lead 
to increased maturation of dendritic cells [77]. These findings were found to have 
the potential to increase the prognosis of HNSCC [79]. The addition of 1,25-
(OH)2D3 to HNSCC cells in vitro [94], as well as adding less hypercalcemic 
vitamin D analogues [81] resulted in a blockage in the transition of cells from G1 
to S phase, inducing G0/G1 cell cycle arrest accumulating both differentiated and 
undifferentiated tumor cells in this phase. Vitamin D analogue was also able to 
“inhibit cellular proliferation of human laryngeal squamous carcinoma cells 
through the cyclin-dependent kinase inhibitor p57 or p21” [79, 81]. The role of 
1,25-(OH)2D3 in suppressing cellular proliferation, apoptosis induction and cell 
cycle arrest as well as down-regulating several angiogenesis factors took place 
under the influence of 1,25-(OH)2D3 action on oral squamous cell carcinoma cells 
of the oral floor [83]. A dose related consequence of the administration of Vitamin 
D3 analogue EB1089 had presented itself in the inhibition of HNSCC cellular 
growth [82], which could be also related to 1,25-(OH)2D3 ability to upregulate the 
expression of cell cycle inhibitory proteins p21 and p18 [121]. 
 
As we find these results to be encouraging, it should be pointed out that more 
effort to define the role of 1,25-(OH)2D3 and its analogues in the chemoprevention 
of OSCC is to be done. In this matter, a very related research done after this 
study supported our findings and provided more evidence about the increased 
VDR expression in OSCC basal cell layer and moreover suggested that 
decreased serum 1,25-(OH)2D3 concentrations enhances oral epithelial 
proliferation [122]. Also recently, the adjuvant combination therapy with 1,25-
(OH)2D3 and Erlotinib, a chemotherapeutic agent, showed more treatment 
efficacy for OSCC [123]. Further studies on other non-hypercalcemic VD 
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analogues will also be valued and may offer therapeutic regimes of fewer side 
effects, preventing the unfavorable responses to increased body calcium levels. 
 
In conclusion, this study provides the first evidence that decreased VDR 
expression in OSCC might be associated with tumor relapse [1, 2][1, 2]. VDR 
expression is found in putative CD44+ CSC compartments, which may represent 
an entrance point for other adjuvant treatment modality for OSCC. 
Chemopreventive therapy using 1,25-(OH)2D3 or its analogues to target adjuvant 
residual tumor cells could be successful, which in turn may help in tuning the 
tumor supportive treatments in the clinic [1, 2]. However, further in vivo and in 
vitro investigations are required to support this hypothesis. 
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F. Summary 
Oral squamous cell carcinoma (OSCC) is the sixth common cancer worldwide. 
Despite the amount of research and the development of diagnosis and treatment 
methods, there is no significant improvement in the patient-survival rates. The 
treatment outcome prognostic and predictive biomarkers in OSCC still lack the 
clinical routine compared with other tumers in other regions of the human body, 
where such biomarkers have been more recognized as causative factors. 
 
In recent studies, it is becoming more evident that most, perhaps all, 
malignancies are developing from the so-called cancer stem cell (CSC) 
compartment. Also from clinical observation, theories suggested the existence of 
residual stem cells after therapy that may be responsible for tumor regeneration, 
which demand developing new treatment modalities that can target the critical 
CSCs regenerating and self-renewal properties. In this manner, CD44, which is 
a cell-surface extracellular matrix receptor, is the most recognized and studied 
CSCs related marker. 
 
Vitamin D (VD) and its metabolites, mainly 1,25-(OH)2D3 are known to regulate 
cell growth maintenance, cellular proliferation, and differentiation induction. 
Accordingly, Vitamin D receptor (VDR) expression is the mediator of anticancer 
VD activity and its analogues in some cancers. In head and neck squamous cell 
carcinoma and OSCC, VDR mediates the inhibition of neoplastic activities and 
cellular growth. 
 
This is the first study to assess the link between putative CSC compartment and 
VDR expression in CD44+ tumor cells. This study was designed to analyze the 
expression of VDR in OSCC and normal mucosal tissue and to identify the 
relation between VDR expression and tumor relapse. 
 
A retrospective analysis demonstrated VDR expression in OSCC and normal 
tissue samples by immunohistochemistry. Immunohistochemical and 
immunofluorescent double labeling experiments for VDR+, with CD44+ and Ki-
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67+ were carried out. VDR expression was analyzed in cells from the OSCC 
BICR3 and BICR56 cell lines in cytospins as positive control of VDR expression 
by cancer cells. VDR gene expression was measured by RT-PCR. Western blot 
analysis confirmed VDR antibody specificity. 
 
This data confirmed that VDR expression is present in both cancer and non-
cancer tissue samples. There was no association between VDR expression and 
clinicopathological characteristics although univariate analysis and multivariate 
analysis showed worse survival rates in OSCC patients with low VDR expression. 
Immunohistochemical double labeling experiments in OSCC tissue serial 
sections and OSCC cell lines confirmed that VDR expression is associated with 
CD44+ tumor cells. Our analysis of immunohistochemical double staining 
experiment data (CD44+/VDR+) showed increased co-expression of VDR+ with 
CD44+ cancer cells. Western blot expression in OSCC cell lines confirmed 
increased VDR expression in OSCC cell lines compared to normal tissue. In both 
tissue samples, VDR expression was mainly restricted to the basal cell layer. 
Correlation analysis from quantified immunohistochemical single staining 
revealed that Ki-67 expression in OSCC is inversely correlated to VDR 
expression.  
 
Our finding supports the hypothesis that increased VDR expression may be 
associated with increased tumor-specific survival amongst patients with high 
VDR expression compared to patients with low VDR. From our results, we 
speculate that the use of 1,25-(OH)2D3 or its non-hypercalcemic analogues as 
adjuvant chemopreventive therapy could be useful. 
 
In conclusion, this study provides the first evidence that decreased VDR 
expression in OSCC might be associated with tumor relapse. However, VDR 
expression found in a putative CD44+ CSC compartment may represent an 
entrance gate for other adjuvant treatment modalities in OSCC. 
Chemopreventive therapy using 1,25-(OH)2D3 or its analogues to target adjuvant 
residual tumor cells could be successful, which in turn may help enhancing tumor 
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supportive treatments in the clinic. However, further in vivo and in vitro 
investigations are required to support this hypothesis. 
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H. Zusammenfassung 
 
Mundhöhlenkarzinome gehören zu der sechsthäufigsten Tumorentität weltweit. 
Trotz Fortschritten in Diagnose und therapeutischen Maßnahmen konnte die 
Überlebensrate von Patienten mit Mundhöhlenkarzinom in den letzten 
Jahrzehnten nicht signifikant gesteigert werden. 
Während für andere Tumorentitäten bereits standardisierte prognostische 
Biomarker identifiziert wurden, fehlen diese bis heute in der klinischen Routine 
für das Mundhöhlenkarzinom. 
Das Ziel dieser Studie war es – anhand eines „Hallmark of Cancer“ 
(Krebsmerkmal) – einen gewebebasierten Biomarker zu analysieren, wodurch 
möglicherweise langfristig eine schonendere und bessere Therapie für Patienten 
mit Mundhöhlenkarzinom angeboten werden kann. 
Der Nachweis einer reduzierten Expression des Vitamin-D-Rezeptors (VDR) in 
Tumorzellen kann als Hinweis auf Apoptoseresistenz verstanden werden. 
Vitamin D (1,25(OH)2D3, 1,25-Dihydroxyvitamin D3, Calcitriol) wirkt vielfältig auf 
den Zellmetabolismus und ist maßgeblich an der Aufrechterhaltung und 
Regulation von normalem Zellwachstum, Reifung von Lymphozyten, Hemmung 
der Proliferation, Karzinogenese und Metastasierung beteiligt. Calcitriol, der 
aktive Metabolit von Vitamin D und Agonist des VDR besitzt antiproliferative, 
proapoptotische und Differenzierung-induzierende Attribute. Außerdem induziert 
Vitamin D Zell-Zyklus-Arrest und ist an der Regulation von Zellwachstum 
involviert, was Calcitiol und synthetische Vitamin-D-Analoga für eine Therapie 
gegen Tumore interessant macht. Aus diesem Grund ist die Untersuchung von 
VDR bei Tumoren ein wichtiger Schritt auf dem Weg zu neuen 
Behandlungsmethoden.   
Eine Expressionsanalyse des VDR wurde beim Mundhöhlenkarzinom bislang 
noch nicht durchgeführt. Diese Studie befasste sich daher insbesondere 
erstmalig mit der Analyse des VDR auf die Prognose des Mundhöhlenkarzinoms.  
Zusammenfassung 
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Für diese Analyse wurden von 191 Patienten mit Mundhöhlenkarzinom 
immunhistochemische Färbungen von VDR und Ki-67 (Proliferationsmarker) 
durchgeführt und die Expressionsanalyse mit klinisch-pathologischen 
Verlaufsparametern assoziiert. 136 Tumorproben (n = 136/191) zeigten eine 
erniedrigte VDR Expression, die mit deutlich reduziertem tumorfreien Überleben 
in Verbindung gebracht wurde. Eine erhöhte VDR Expression war mit einer 
besseren Prognose assoziiert. In Tumorzelllinien des Mundhöhlenkarzinoms 
konnte durch die Genexpressionsanalyse (mittels RT-PCR) eine erhöhte VDR 
Expression analysiert werden. Der VDR Antikörper konnte durch Western Blot 
Analyse in Proteinlysaten von Tumorzellkulturen spezifische VDR positive 
Banden aufzeigen. Eine immunhistochemische Doppelmarkierung demonstrierte 
u.a. in der basalen Epithelzellschicht eine Co-expression VDR positiver 
Tumorzellen mit CD44 positiven Tumorzellen. Eine Immunfluoreszenz-
Doppelmarkierung zeigte die Mehrzahl proliferierender (Ki-67) Tumorzellen ohne 
oder mit geringer VDR Expression und bestätigte die inverse Korrelationsanalyse 
von Ki-67 mit VDR aus den Ergebnissen der immunhistochemischen 
Einfachmarkierungen.  
Auf Basis der erzielten Ergebnisse aus dieser Studie kann schlussgefolgert 
werden, dass zwar die Expression des VDRs keinen Einfluss auf klinisch-
pathologische Verlaufsparameter (Tumorgröße, Tumorstadium, Metastasierung, 
Grading) zu haben scheint, jedoch mit tumor-spezifischem Überleben assoziiert 
ist.  
Die in dieser Arbeit erzielten Ergebnisse können zu einem besseren Verständnis 
der prognostischen Relevanz des VDRs beim Mundhöhlenkarzinom beitragen. 
Diese basiswissenschaftlichen Ergebnisse tragen dazu bei, in Zukunft 
notwendige Therapieentscheidungen zu ergänzen. Insbesondere weiterführende 
klinische Arbeiten zur funktionellen Rolle von Calcitriol auf die Lebensqualität und 
das Langzeitüberleben von Patienten mit Mundhöhlenkarzinom sind unerlässlich 
und Gegenstand aktueller Therapiekonzepte bei anderen Tumorentitäten (z.B. 
beim malignen Melanom oder Mammakarzinom). 
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FFPE Formalin-fixed paraffin-embedded 
Fig. Figure 
FITC Fluoresceinisothiocyanate 
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GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
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HR Hazard ratios 
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M Male 
mAb Mouse antibody 
MRI Magnetic resonance imaging 
mRNA Messenger RNA 
OSCC Oral squamous cell carcinoma 
p P-value 
pAb Primary antibody 
PET Position emission tomography  
pM Stage of distant metastasis (according to 
UICC) 
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(according to UICC) 
pT Size of tumor (according to UICC) 
RNA Ribonucleic acid 
ROC Receiver Operating Characteristics  
Rr Pearson's correlation index  
RT-PCR Reverse transcription polymerase chain 
reaction  
UICC Union for International Cancer Control 
UK United Kingdome 
USA United States of America 
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VDR Vitamin D receptor 
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Y Years 
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L. Figures 
FIGURE 1: HISTOPATHOLOGICAL STAGES OF MALIGNANT TRANSFORMATION IN EPITHELIAL SQUAMOUS CELL CARCINOMA 
(HNSCC TISSUE SAMPLES). STAGES OF MALIGNANT TRANSFORMATION IN WHICH NORMAL EPITHELIAL TISSUE (SLIDE A) 
UNDERGOES HYPERPLASTIC CELLULAR ACTIVITY TO FROM EPITHELIAL HYPERPLASIA (SLIDE B). PERSISTENT ETIOLOGICAL 
FACTORS THEN LEAD TO MILD DYSPLASIA (SLIDE C) THEN TO THE LAST PRECANCEROUS LESION; CARCINOMA INSITU 
(SLIDE D) AND FINALLY REACHING THE PHASE OF INVASIVE SQUAMOUS CELL CARCINOMA (SLIDE E). CLINICALLY, 
HYPERPLASTIC CHANGES NEED AT LEAST REGULAR PROFESSIONAL CONTROL WHILE DYSPLASTIC TO INVASIVE NEOPLASTIC 
CHANGES DEMAND SURGICAL INTERVENTION OR OTHER CANCER THERAPY. MODIFIED FROM [4]. ........................... 2 
FIGURE 2: CD44S AND CD44V CELLULAR MARKERS. THE STRUCTURE OF THE VARIANT ISOFORM (CD44V) AND THE STANDARD 
ISOFORM (CD44S). HYALURONIC ACID BINDS ITSELF TO THE ‘’N-TERMINAL OF THE EXTRACELLULAR DOMAIN’’ 
RESULTING IN THE ACTIVE FORM OF CD44. CD44 IS IMPORTANT MARKER IN CANCERS LIKE ORAL SQUAMOUS CELL 
CARCINOMA, HEAD AND NECK CANCER, BREAST CANCER ETC.. CD44V ISOFORM IS BELIEVED TO HAVE NEOPLASTIC 
ACTIVITIES MODIFIED FROM [3] ............................................................................................................ 7 
FIGURE 3: ORGANIC STRUCTURE OF 1,25-DIHYDROXYCHOLECALCIFEROL OTHER SCIENTIFIC NAMES INCLUDE 1,25-
DIHYDROXYVITAMIN D3 (ABBREVIATED 1,25-(OH)2D3) WHICH IS COMMONLY KNOWN AS CALCITRIOL. .................. 8 
FIGURE 4: RECEIVER OPERATING CHARACTERISTICS (ROC) CURVE FOR VDR EXPRESSION IN OSCC PATIENTS [1, 2]. FOR THE 
MEASUREMENT OF THE CUTOFF POINT, SENSITIVITY (THE TRUE POSITIVE RATES) ARE PLOTTED IN FUNCTION OF FALSE 
POSITIVE RATES (100-SPECIFICITY): THE ARROW REPRESENTS THE CUTOFF VALUE WITH HIGHEST DIAGNOSTIC ACCURACY 
OF VDR EXPRESSION ANALYZED AT 39% FOR THE DIAGNOSIS OF RECURRENT GROUP. (SENSITIVITY= 94.12 %, 95 % CI 
83.8–98.8 %; SPECIFICITY= 36.43 %, 95 % CI 28.5–45.0 %). DOTTED LINES SHOW 95 % CI [1, 2, 104]. ....... 24 
FIGURE 5: IMMUNOHISTOCHEMICAL SINGLE STAINING (VDR, CD44) AND DOUBLE STAINING (VDR WITH CD44) OF SERIAL 
SECTIONS IN OSCC (MAGNIFICATION ×200-FOLD) [1, 2]. NOTE THE FORMATION OF EPITHELIAL CELLS WITHIN 
EPITHELIAL LAYER(ASTERISKS). THE AREA OF INTEREST IS SHOWED IN THE SMALL BOX. SLIDES A, B REPRESENTS IMAGES 
OF VDR EXPRESSION AND CD44 IN SLIDES C, D VDR WITH CD44 SINGLE AND IMMUNOHISTOCHEMICAL DOUBLE 
STAINING IN SLIDE E. SLIDE F SHOWS IGG CONTROL WITH NO STAINING. IN SLIDES B, D: THE STAINING PARTS OF 
‘’COMPUTER-ASSISTED SEMI-QUANTITATIVE ANALYSIS’’ ON VDR+ AND CD44+ OSCC CELLS IS SHOWN, WHERE RED 
LABELS B, D REPRESENT HEAVY OR COMPLETE STAINING AND GREEN LABELS REPRESENT WEAK OR WEAKER STAINING. IN 
SLIDES A, E, BROWN CHROMOGEN COLOR (3,3ʹ-DIAMINOBENZIDINE) INDICATES POSITIVE VDR AND IN SLIDE C 
INDICATES CD44 STAINING. IN SLIDE E, RED CHROMOGEN COLOR (FAST RED) OF DOUBLE STAINED TUMOR CELLS SHOWS 
CD44+ CELLS AND THE BLUE COLOR INDICATES THE NUCLEAR COUNTERSTAINING BY HEMATOXYLIN. THE STRONG 
PRESENCE OF VDR AND CD44 EXPRESSION IN THE EPITHELIAL BASAL LAYER CELLS IS NOTED [1, 2]. ...................... 25 
FIGURE 6: VDR EXPRESSION WITHIN BICR3 AND BICR56 OSCC CELL LINES. SLIDES A-D REPRESENT THE 
IMMUNOCYTOCHEMICAL SINGLE AND DOUBLE STAINING OF VDR EXPRESSION. SLIDES E, F REPRESENTS WESTERN BLOT 
ANALYSIS OF VDR EXPRESSION. SLIDE A SHOWS IMAGES OF IGG CONTROL. SLIDE B SHOWS IMAGES OF VDR 
EXPRESSION IN BICR3 CELL LINES. SLIDE C SHOWS IMAGES OF VDR EXPRESSION IN BICR56 CELL LINES. SLIDE D SHOWS 
IMAGES OF IMMUNOCYTOCHEMICAL DOUBLE STAINING OF VDR IN BROWN AREAS (3,3ʹ-DIAMINOBENZIDINE) SHOW 
WITH BROWN ARROWS. CD44 IMMUNOCYTOCHEMICAL DOUBLE STAINING IN RED  AREAS (FAST RED) SHOWED WITH 
RED ARROWS. ORIGINAL MAGNIFICATION IS ×400-FOLD. IN SLIDE E, THE SPECIFICITY OF IMMUNOHISTOCHEMICAL 
STAINING AND INCREASED VDR EXPRESSION IN COMPARISON TO NORMAL TISSUE WAS CONFIRMED BY WESTERN BLOT 
OF VDR IN BICR3 AND BICR56 OSCC CELL LINES. THE GRAPH F REPRESENTS A DENSITOMETRIC QUANTIFICATION OF 
WESTERN BLOT PROTEIN BANDS IN PIXEL TOTAL VDR EXPRESSION IN BICR3 AND BICR56 AND NORMAL TISSUE. AS 
PREDICTED, THE DETECTED MOLECULAR WEIGHT OF VDR IS IN ACCORDANCE WITH THE PREDICTED MOLECULAR WEIGHT 
OF 50 KDA. GAPDH (LOADING CONTROL), WHICH IS DETECTED AS A BAND OF APPROXIMATELY 35 KDA [1, 2]....... 26 
FIGURE 7: CORRELATION AND CO-EXPRESSION ANALYSIS OF VDR WITH KI-67. CALIBRATION BAR REPRESENTS 25 ΜM[1, 2]. 
IMMUNOFLUORESCENT DOUBLE STAINING OF VDR WITH KI-67 CONFIRMS THE IMMUNOHISTOCHEMICAL SINGLE 
STAINING RESULTS IN OSCC FFPE TISSUES. SLIDE A SHOWS THE CORRELATION ANALYSIS OF VDR WITH KI-67 FROM 
QUANTIFIED IMMUNOHISTOCHEMICAL SINGLE STAINING RESULTS OF VDR (MEASURED IN %) IN OSCC FFPE TISSUES 
WITH PROLIFERATING CELLS (KI-67 MEASURED IN %), KI-67 EXPRESSION IN OSCC HAD A WEAK BUT SIGNIFICANT 
INVERSE CORRELATION WITH THE EXPRESSION OF VDR (R=−0.4308, P<0.0001). SLIDE B REPRESENTS THE KI-67 
EXPRESSION (RED, CY), SLIDE (C) REPRESENTS VDR EXPRESSION (GREEN, FITC). SLIDES D, E SHOWS THE CO-
EXPRESSION IN OSCC FFPE TISSUES SHOWING THE MAJORITY OF PROLIFERATING (KI-67+) CANCER CELLS WITHOUT 
VDR EXPRESSION (ASTERISKS, MERGE). TO ADJUST A BETTER CONTRAST, CO-EXPRESSION OF VDR/KI-67 IS 
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DEMONSTRATED WITH (LEFT, SLIDE D) AND WITHOUT (RIGHT, SLIDE E) NUCLEAR COUNTERSTAINING (BLUE, DAPI). 
WHITE DOTTED ARROWS POINT TO AREAS OF INCREASED COEXPRESSION INDICATING THAT VDR EXPRESSING CANCER 
CELLS ARE SELDOM STRONGLY ASSOCIATED WITH PROLIFERATING CELLS BUT MAINLY DETECTED WITHOUT OR WITH 
WEAK KI-67 EXPRESSION (WHITE ARROWS). CO-LOCALIZATION PARAMETER (MERGE, SLIDES D, E) OF KI-67/VDR (RED 
AND GREEN) MEASURED BY PEARSON'S CORRELATION (RR) INDEX IS ANALYZED AT 0.08. FITC, 
FLUORESCEINISOTHIOCYANATE, CY3, CYANINE 3 RED, AND DAPI 4ʹ,6-DIAMIDINO-2 PHENYLINDOLDIHYDROCHLORIDE 
[1, 2, 100]. ................................................................................................................................... 27 
FIGURE 8: SURVIVAL CURVES OF OSCC PATIENTS MEASURED BY VDR EXPRESSION [1, 2]. CURVE A: KAPLAN–MEIER CURVE 
SHOWS SURVIVAL FOR DISEASE-SPECIFIC SURVIVAL (DSS) STRATIFIED BY HIGH VDR EXPRESSION (BLACK LINE) AND LOW 
VDR EXPRESSION (DOTTED LINE). CURVE B: COX REGRESSION CURVE SHOWS SURVIVAL FOR DISEASE-SPECIFIC SURVIVAL 
(DSS) STRATIFIED BY HIGH VDR EXPRESSION (BLACK LINE) AND LOW VDR EXPRESSION (DOTTED LINE). LOW VDR 
EXPRESSION (N=136/191) IN OSCC IS FOUND TO BE ASSOCIATED WITH POORER SURVIVAL. DSS 1-, 3-, AND 5-YEAR 
SURVIVAL RATES (VDR HIGH VS. VDR LOW) IN UNIVARIATE KAPLAN- MEIER SURVIVAL CURVE (A) ARE 100 % VS. 97 
%, 94 %, VS. 78 %, AND 94 % VS. 65 %, RESPECTIVELY. THE TIMES OF THE CENSORED DATA ARE INDICATED BY SHORT 
VERTICAL LINES. DSS 1-, 3-, AND 5-YEAR SURVIVAL RATES (VDR HIGH VS. VDR LOW) IN MULTIVARIATE COX 
REGRESSION (B) SURVIVAL CURVE ARE 100 % VS. 99 %, 96 %, VS. 82 %, AND 94 % VS. 65 %, RESPECTIVELY [1, 2].
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M.  Tables 
Table 1: Clinicopathological characteristics and prognostic factors of 191 patients with OSCC of low and high VDR 
expressers. Cutoff value for VDR expression was determined by Receiver Operating Characteristics (ROC) analysis [1, 
2]. 
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